Winston-Salem, N.C. - Even before lesions begin to improve, patients with moderate to severe plaque psoriasis feel better a few weeks after starting efalizumab (Raptiva) therapy.
The Weekly Roundup: July 22-26
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Study Highlights Efficacy of Lotion with Biotechnological Phytocomplex, Niacinamide, and Succinic Acid in Enhancing Microbiota Diversity and Reducing Acne Severity
The FDA Approves Deuruxolitinib for Severe Alopecia in Adults